Findings showed no significant reduction in cognitive or functional decline with simufilam when compared with placebo. Topline results were announced from a phase 3 trial evaluating simufilam, an oral ...

Please provide your email address to receive an email when new articles are posted on . Topline results from the phase 3 ReThink-ALZ study of simufilam in mild to moderate Alzheimer’s disease showed ...

No significant reduction in cognitive or functional decline was observed with simufilam compared with placebo. A phase 3 trial evaluating simufilam for the treatment of Alzheimer disease (AD) did not ...

Cassava Sciences Inc. (NASDAQ:SAVA) on Tuesday shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease. REFOCUS-ALZ randomized approximately ...

Cassava Sciences' presentation at the CTAD Conference undermines its claim that simufilam is an effective treatment for Alzheimer's Disease. The drug appears to have little to no effect on moderate ...

The third interim safety review for simufilam showed no significant safety concerns, particularly regarding amyloid-related imaging abnormalities (ARIAs). Despite interim safety results, simufilam's ...

An independent DSMB reviewed interim safety data for simufilam and recommended the trials proceed without modifications. Two ongoing trials with over 1,900 Alzheimer’s patients; top-line results from ...

A scientist looks at hypometabolic and hypoperfusion patterns at the single-subject level from a patient suffering from Alzheimer's disease at the Memory Centre at the Department of Readaptation and ...

AUSTIN, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for ...

That’s what the label on the side of the bottle says, and that’s what you’ll do. You want to feel better soon — your health and well-being are important — so you’ll do as you’re told and follow all ...